Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
NCT Number: NCT07281911
Sepsis-associated acute respiratory distress syndrome (ARDS) is one of the deadliest and most biologically heterogeneous forms of respiratory failure. Despite uniform diagnostic criteria, patients with septic ARDS show wide variability in inflammatory intensity, alveolar epithelial and endothelial injury, alveolar fluid composition, ventilatory mechanical properties, and clinical evolution. Early identification of these differences may enable better prognostication and more precise treatment.
This prospective observational study aims to deeply characterize the earliest phases of septic ARDS by integrating serial bronchoalveolar lavage (BAL) at 0, 24 and 72 hours with parallel plasma biomarker profiling and detailed mechanical ventilation data. This design captures the evolving biological and physiological landscape of septic ARDS during its most dynamic window. The central goal is to identify systemic, alveolar, and hybrid bio-mechano-inflammatory subphenotypes that can inform personalized approaches to support, risk stratification, and future interventional trials.
Trial opening soon.
Get Notified18 year and older
All sexes
Observational
Barcelona, 08035, Spain
Acute respiratory distress syndrome caused by sepsis is not a uniform disease but a syndrome comprising multiple biological and mechanical states. The Berlin Definition provides a useful clinical entry point but does not capture the profound heterogeneity found in molecular pathways, alveolar immune activation, epithelial disruption, endothelial dysfunction, and mechanical ventilation responses.
The first 72 hours of ARDS represent a critical, rapidly evolving biological landscape where systemic cytokine release, alveolar epithelial injury, endothelial activation, and capillary-alveolar permeability all fluctuate dramatically. These early shifts are believed to determine downstream trajectories such as ventilator dependence, multiorgan dysfunction, and mortality. Capturing this dynamic process requires repeated sampling at predefined intervals rather than the traditional single one-time measurement.
ARDS emerges primarily within the alveolar space; yet most studies rely exclusively on plasma biomarkers, which provide only a partial window into the alveolus. The pulmonary compartment often behaves independently of the systemic circulation due to the compartmentalization of inflammatory mediators. BAL sampling therefore offers a unique opportunity to interrogate the lung directly. On the other hand, ventilatory mechanics-in particular driving pressure, plateau pressure, lung compliance, and ventilatory ratio-reflect the biomechanical stress conditions imposed on the lung, which may interact with or even exacerbate biological injury.
Thus, inflammation, epithelial damage, endothelial leak, alveolar flooding, and mechanical stress constitute interdependent dimensions of the early ARDS process.
This study integrates:
This multidimensional dataset is designed to reveal biological, mechanical, and hybrid subphenotypes which could explain why patients who are clinically similar diverge into starkly different trajectories.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: From enrollment to 72 hours
Identification of early alveolar inflammatory subphenotypes, defined by trajectories of BAL biomarkers (IL-6, IL-8, IL-10, TNF-α, sRAGE, KL-6, SP-D, Ang-2, vWF, total protein, albumin) and Mechanical Profiles in Sepsis-Associated ARDS.
Contact information is provided by the study sponsor or research team.
Luis Chiscano Camon, MD, PhD
CONTACT
Maria Martínez Pla, MD
CONTACT
Hospital Universitari Vall d'Hebron Research Institute
Other
Characterization of Early Biological and Mechanical Profiles in Sepsis-Associated ARDS for Studying Compartamentalization (Serial Bronchoalveolar Lavage and Plasma Biomarkers) to Identify Inflammatory and Hybrid Subphenotypes
Acronym: EARLY-SARDS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04568642
Acute Hypoxemic Respiratory Failure, Acute Hypoxemic and Hypercapnic Respiratory Failure
Izmir, Turkey/izmir, Turkey (Türkiye)
View Trial DetailsNCT07452406
Acute Hypoxemic Respiratory Failure, High-Flow Nasal Cannula Therapy
Chicago, Illinois, United States
View Trial DetailsNCT07460427
Acute Hypoxemic Respiratory Failure, Respiration Disorders
Kigali, Rwanda
View Trial DetailsNCT07463885
Acute Hypoxemic Respiratory Failure, Acute Respiratory Distress Syndrome (ARDS)
View Trial Details